BridgeBio Pharma, Inc. — Director's Dealing 2020

Sep 30, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-09-25

Reporting Person: HOMCY CHARLES J (Director, Chairman of Pharmaceuticals)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-25	Common Stock	S	65661	$36.6822	Disposed	1237363	Direct
2020-09-25	Common Stock	S	15396	$37.4685	Disposed	1221967	Direct
2020-09-29	Common Stock	S	18200	$37.50	Disposed	1203767	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020.

F2: Represents the weighted average sale price of the shares sold from $36.26 to $37.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 4.

F3: Includes 733 shares acquired by the Reporting Person on August 14, 2020 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

F4: Represents the weighted average sale price of the shares sold from $37.26 to $37.66 per share.